Covid

Dosing intervals for COVID-19 mRNA Vaccine

Jan 14, 2021 | Beth Hess

On January 6, CDC revised Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States. The portion regarding dosing intervals is summarized below:

  • Routine Scheduling. Do not schedule people to receive dose #2 earlier than recommended (i.e., 21 days for Pfizer-BioNTech or 28 days for Moderna).
  • Inadvertent Early Doses. Dose #2 inadvertently administered as much as 4 days too early (“grace period”) should be considered valid.
  • No Maximum Interval. There is no maximum interval between dose #1 and dose #2 for either vaccine. If dose #2 is administered beyond 21 or 28 days, there is no need to restart the series or repeat the dose.
  • Errors. Vaccine administration errors should be reported to the Vaccine Adverse Event Reporting System (VAERS).

Visit CDC’s COVID-19 Vaccination: Clinical Considerations gateway page for more information.


About Beth Hess

More posts by Beth Hess

Related Posts

I Stock 1200923834 Mother and baby 1
  • HIV, STI, & Viral Hepatitis

NACCHO and CDC Seeking Information on Congenital...

NACCHO, in conjunction with CDC, is interested in collecting information on...

Feb 22, 2021 | Shalesha Majors

NACCHO and CDC Seeking Information on Congenital...

Falls statistic V2
  • Healthy Living & Prevention
  • Research & Reports

New Issue Brief Highlights Adult Fall Prevention

This issue brief highlights the prevalence of falls in community-dwelling older...

Feb 21, 2021 | Andrea Grenadier

New Issue Brief Highlights Adult Fall Prevention

  • Maternal, Child, & Adolescent Health

RFP: Action Planning Facilitation Consultant for the...

NACCHO is seeking a qualified consultant to develop and facilitate action...

Feb 18, 2021 | Hitomi Abe

RFP: Action Planning Facilitation Consultant for the...

Laboratory 3827736 1920
  • COVID-19
  • HIV, STI, & Viral Hepatitis

Supply Shortages Impacting COVID-19 and Non-COVID Testing

Over a third of laboratories in a recent American Society for Microbiology...

Feb 18, 2021 | Julia Zigman

Supply Shortages Impacting COVID-19 and Non-COVID Testing

National Native HIV Network v2
  • HIV, STI, & Viral Hepatitis

Open Call for Historical Content 

OURStory is a historical account celebrating the contributions that American...

Feb 18, 2021 | Shalesha Majors

Open Call for Historical Content 

Opioid
  • Opioid Overdose Epidemic

Trends and Geographic Patterns in Drug and Synthetic...

A new CDC report demonstrates significant increases in deaths involving...

Feb 18, 2021 | Julia Zigman

Trends and Geographic Patterns in Drug and Synthetic...

HIV COVID
  • COVID-19
  • HIV, STI, & Viral Hepatitis

Big Ideas in Brief on HIV Telehealth and Supporting HIV...

Two new one-pagers are available from the O’Neill Institute for National and...

Feb 18, 2021 | Julia Zigman

Big Ideas in Brief on HIV Telehealth and Supporting HIV...

Cdc badge small
  • COVID-19
  • HIV, STI, & Viral Hepatitis

New CDC People with HIV and COVID-19 Fact Sheet

The Centers for Disease Control and Prevention (CDC) recently updated a fact...

Feb 18, 2021 | Shalesha Majors

New CDC People with HIV and COVID-19 Fact Sheet

LGBTQ Inclusive Care
  • HIV, STI, & Viral Hepatitis

Resource: Using Affirming Language with LGBTQIA+ Patients

This resource offers guidance on asking patients about their gender identity...

Feb 18, 2021 | Julia Zigman

Resource: Using Affirming Language with LGBTQIA+ Patients

Back to Top